Table 1 Base-case analysis.

Index	Risk	Strategy	Total			Incremental			ICER
Index	Risk	Strategy	Cost ($)	QALYs	LYs	Cost ($)	QALYs	LYs	($/QALY)	($/LY)
FLI	Low < 60	Screening	16,957	11.832	14.006	2101	0.013	0.013	161,675	16,957
	Low < 60	No screening	14,856	11.819	13.993					14,856
	High ≥ 60	Screening	27,748	11.406	13.620	2943	0.037	0.035	78,647	27,748
	High ≥ 60	No screening	24,805	11.369	13.585					24,805
HSI	Low < 36	Screening	18,090	11.788	13.965	2205	0.015	0.014	150,458	18,090
	Low < 36	No screening	15,885	11.773	13.951					15,885
	High ≥ 36	Screening	25,407	11.499	13.704	2757	0.032	0.031	84,874	25,407
	High ≥ 36	No screening	22,650	11.466	13.673					22,650

FLI fibrosis liver index, HSI hepatic steatosis index, ICER incremental cost-effectiveness ratio, LY life year, QALY quality-adjusted life year.

Quick links

Search